Establishment of a murine model of malignant mesothelioma.
about
Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.Identification of novel autoantibodies for detection of malignant mesotheliomaMinimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesotheliomaA Subset of Malignant Mesothelioma Tumors Retain Osteogenic PotentialFTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse modelSerologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.Intraoperative Molecular Imaging of Lung Adenocarcinoma Can Identify Residual Tumor Cells at the Surgical MarginsLow-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.Presence of WT1, the Wilm's tumor suppressor gene product, in nuclear poly(A)(+) ribonucleoprotein.Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cellsNeoadjuvant anti-tumor vaccination prior to surgery enhances survival.Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cellsGeneration and characterization of an ascitogenic mesothelin-expressing tumor model.Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen.Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma.Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessmentAntitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.The Role of Regulatory T Cells in Mesothelioma.Intraoperative near-infrared imaging of surgical wounds after tumor resections can detect residual disease.Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer.The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancerA positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.Fowlpox-based survivin vaccination for malignant mesothelioma therapyPD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in micePotentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapyInduction of tunica vaginalis mesotheliomas in rats by xenobiotics.Transient Treg depletion enhances therapeutic anti-cancer vaccination.Increasing dietary selenium elevates reducing capacity and ERK activation associated with accelerated progression of select mesothelioma tumors.A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma.IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice.Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy.Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.Spontaneously immortalized mouse mesothelial cells display characteristics of malignant transformation.
P2860
Q54607618-8D489A7D-475C-4EEA-833E-CC52AF8042F1Q54607623-8B526A9C-56B1-414D-9172-F0C464D33DF9Q54607624-7633CE13-7920-473B-9E53-3FBD43D0089FQ54607676-B9C04B79-5D77-4C67-89BC-31C53AD2D2DCQ54607684-D82C6E8A-22BF-41D6-BDBC-74790BCA2946Q54607920-066B0843-C0F5-4B61-BDCF-3E941505B334Q54607925-3B9121EC-23C3-4BE1-B04D-615074F14170Q54607939-CAE325BB-D772-4F1F-AF50-18D9E967487BQ54607942-2D75E579-9185-493F-AF1C-56949599409AQ54607945-FDAD9E20-8AD9-41D4-BDF8-2A91E340E829Q54608065-F18A42AA-8B43-4895-8991-71E38CBDC6FEQ54608069-B5934163-5CA0-42C9-AB53-F006FC026898Q54608070-F4B4C512-290A-4382-A295-6B6F4E19C448
P1343
Q27333517-1F517F69-CE50-4FF5-9C76-3C82C106234CQ28387447-193D6492-D005-4E6E-ACD2-83E0A032C4BFQ28389071-563704DD-FBAD-412F-9F9A-2296BCB8E561Q28394868-39CA8504-CB0C-498E-9958-27E97D3A196FQ29248124-3E180EFF-7634-4BA5-BF07-D9FB3FDD49A5Q30863574-21C49EAE-988B-4EA3-8CE1-2A30208E6135Q33755896-092BA8A9-22A5-4972-B1BF-75AECF817060Q33808756-F23F3A37-1631-4C8E-804A-6533B8AE3999Q33871059-066DE02C-D06F-4E2E-9EAC-79C0544E76C7Q33883341-34C883E8-FBDD-47FB-A60A-AD29201AC475Q34076126-81CE5320-EEAC-4C17-B839-41D782867B39Q34145877-079410AF-0865-40B3-92F0-00AD342EB209Q34610483-10DF7C6A-01C2-417C-913E-997D390D61D6Q34832951-63DB3741-30F5-4DD7-B390-792CF1388DBDQ35236067-822FE2F1-C2B9-42DD-9CFD-CA91A65C28D2Q35799065-4C813D03-4947-4FFE-AE91-F22F4720EEFBQ35872350-20605BF9-4B82-4B5D-AAE2-6338D19ADBAAQ35963695-993A5A73-2314-4858-A0AC-DE7FC4D4FEEEQ35964158-37F4120A-8DAD-4F50-BA2E-88DFB79A5AEBQ36060324-54016DA2-E201-49E9-80B2-2D159B8EC47BQ36101238-54A7D45C-84C3-400E-9E56-0D6D1E20D40EQ36351260-7B22966D-CADE-4065-A04D-50D037C73C15Q36568667-0F91F37C-5E96-439A-B764-369020FB978DQ36639456-32BE3BFA-B392-44E5-AC96-27B007737215Q36709317-EBAEA90A-CBEA-4B82-83C1-47541CE40812Q36710130-71A8DD2E-0473-469D-ADF8-EF8AF91356DCQ36821243-17EC551A-DA47-4DB5-9495-98A79EDB151FQ36874759-74B29EFC-EC00-431A-BE89-643469074428Q36890963-3131131C-18D7-4715-8D1F-9FF57B9353C9Q36984486-AD799655-CFF8-4121-94A9-C6C79FCD7720Q37087603-C20E3379-D47C-4B6A-9CBB-B35FC8B3576DQ37526974-0776ECF0-C3DF-4212-963F-46DF48A1B0C2Q37660771-BC92A0E6-7914-4ED3-838D-B20FCAA1BDE0Q37672887-11AE87B5-6F89-452A-8C7C-372CE47A0E25Q38966046-E7AD0A60-2A54-425E-946F-E3FFD57D675CQ39003110-7510F428-8ACD-491E-92BD-0291F73F4327Q39005715-B3D05002-D1CE-4724-8C33-BE369FE5F0E6Q39393666-C2B02696-73F5-4A3D-B08E-6865F84507EEQ39796367-456D4C45-8989-4856-B4D6-8A5BB9C5170AQ39911135-6C0E0C11-7C23-4EBC-9152-B15905A2CF8E
P2860
Establishment of a murine model of malignant mesothelioma.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Establishment of a murine model of malignant mesothelioma.
@en
Establishment of a murine model of malignant mesothelioma.
@nl
type
label
Establishment of a murine model of malignant mesothelioma.
@en
Establishment of a murine model of malignant mesothelioma.
@nl
prefLabel
Establishment of a murine model of malignant mesothelioma.
@en
Establishment of a murine model of malignant mesothelioma.
@nl
P2093
P2860
P4510
P356
P1476
Establishment of a murine model of malignant mesothelioma.
@en
P2093
B W Robinson
D Whitaker
L S Manning
M J Garlepp
P2860
P304
P356
10.1002/IJC.2910520609
P577
1992-12-01T00:00:00Z